CG Oncology, Inc. Common stock
Price Action
Technical Summary
STAGE 2 UPTRENDCG Oncology, Inc. Common stock is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings contraction of 90% provides fundamental context to the price action. Investors should exercise caution due to high volatility (72% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $54.03 | +8.82% | ABOVE |
| 50 SMA | $49.96 | +17.69% | ABOVE |
| 100 SMA | $45.95 | +27.97% | ABOVE |
| 150 SMA | $40.91 | +43.74% | ABOVE |
| 200 SMA | $37.22 | +57.96% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CGON in an uptrend right now?
CGON has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CGON is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is CGON overbought or oversold?
CGON's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is CGON outperforming the market?
CGON has a Relative Strength (RS) Rating of 93 out of 99. Yes, CGON is a market leader, outperforming 93% of all stocks over the past 12 months.
Where is CGON in its 52-week range?
CGON is trading at $58.80, which is 98% of its 52-week high ($60.00) and 97% above its 52-week low ($14.80).
How volatile is CGON?
CGON has a Beta of 1.55 and 52-week volatility of 72%. It's more volatile than the S&P 500 - expect bigger swings.